Global High-Flow Nasal Cannula Market Overview
High-Flow Nasal Cannula Size was valued at USD 7.9 Billion in 2023. The high-flow nasal cannula market industry is projected to grow from USD 8.9 Billion in 2024 to USD 21.0 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.00% during the forecast period (2024 - 2032). The main market drivers of revenue growth for high-flow nasal cannulas are the growing number of elderly persons who are more susceptible to respiratory problems and need continuous oxygen therapy, as well as the increasing prevalence of respiratory diseases worldwide.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
High-Flow Nasal Cannula Market Trends
-
Growing respiratory cases are driving the market growth
The market CAGR for high-flow nasal cannulas is growing because of the increasing prevalence of respiratory conditions such as asthma, sleep apnea, and COPD. Asthma and sleeping disorders frequently interrupt breathing during sleep. Nasal cannulas are included in the treatment when CPAP therapy is advised for sleep apnea. A survey conducted among individuals aged 30-70 from 164 countries found that 202,157,057 out of 1,513,628,587 females (13.4%) globally have mild SA, as reported in a March 2023 Oxford Academics article. Moderate SA affects 14.6%, 15.3% and 10.6% of wealthy females, moderately affluent females and somewhat affluent females, respectively, while affecting 23.5, 18.3% and 16.3% of wealthy males, moderately affluent males and somewhat affluent males; therefore, it’s expected that adult sleep apnea will continue to increase leading to higher needs for nasal cannulas thus driving up CAGR in high flow nasal cannula market.
Due to an aging populace, there will be a rapid increase in future growth rates within this industry; seniors are defined as anyone aged over 65 years old, and they account for most patients but not all who require acute care services such as nursing homes, etc. A high-flow oxygen therapy system can be used safely and effectively among elderly patients with acute respiratory failure when conventional methods fail to elicit a response, or noninvasive ventilation (NIV) cannot be tolerated due to intolerance or contraindication against it without meeting criteria for intensive care unit (ICU) admission. Consumer demand for high-flow nasal cannulas is rising because respiratory ailments, including asthma, sleep apnea, and COPD, are becoming more common, thus expanding the market. November of 2022 saw a significant moment in England and Wales’s demographic history when the number of people aged 65 and over, reached 11 million, accounting for 18.6% of the total population, according to the National Statistical Institute of UK and Office for National Statistics. The intriguing thing about this group is that there were more than half a million elderly persons — specifically 527900. Hence, we are now experiencing a high demand for high-flow nasal cannulas due to the increasing number of old people.
An increasing need for high-flow nasal cannulas is expected with wider corporate initiatives and more acceptance towards different business strategies such as partnerships, collaborations, or product launches, which will drive expansion in this industry; an example can be seen during March 2020 when Masimo – a global leader in noninvasive monitoring technologies – acquired TNI Medical AG; an innovative ventilator manufacturer based at Würzburg, Germany. This strategic acquisition has the potential to greatly benefit Masimo's lineup of products. Masimo aims to expand the use of its technology in a growing worldwide market, particularly in the area of nasal insufflation therapy, by leveraging TNI's vast engineering and commercial expertise. Thus, driving the high-flow nasal cannula market revenue.
High-Flow Nasal Cannula Market Segment Insights
High-Flow Nasal Cannula Component Insights
The High-Flow Nasal Cannula segmentation, based on component, includes Nasal Cannulas, Air Humidifiers, Single Heated Tubes, Air/Oxygen Blenders, and Others. In 2023, the nasal cannulas segment dominated the market. The growth of this market is being fueled by two key factors: the comfort level for patients and the ease of use of nasal cannulas. Medical professionals love nasal cannulas because they are easy to insert and remove. Nasal cannulas are widely used for delivering oxygen and other respiratory gases, especially among patients with Acute Respiratory Distress Syndrome (ARDS) or Chronic Obstructive Pulmonary Disease (COPD).
High-Flow Nasal Cannula Application Insights
The High-Flow Nasal Cannula segmentation, based on application, includes Carbon Monoxide Toxicity, Acute Respiratory Failure, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD), Sleep Apnea, and Others. The chronic obstructive pulmonary disease (COPD) category generated the most income in 2023. Airflow obstruction is an undeviating feature of chronic obstructive pulmonary disease (COPD), a respiratory ailment that includes emphysema and chronic bronchitis. One effective way for patients to manage their breathing problems is through the use of nasal cannulas. It has been estimated that hypoxemia, an abnormally low concentration of oxygen in arterial blood, affects as many as 70% or more persons with COPD. In this case, additional oxygen therapy may be prescribed, which can be done by frequently using a nasal cannula to increase oxygen levels while decreasing symptoms such as dyspnea.
High-Flow Nasal Cannula End-user Insights
The High-Flow Nasal Cannula segmentation, based on end-user, includes Long-Term Care Centers, Hospitals, Ambulatory Care Services, and Others. The hospitals category generated the most income in 2023. This can be attributed mainly to two factors: the increasing demand for noninvasive ventilators in hospitals and rising cases of respiratory diseases worldwide. Furthermore, the presence of highly skilled healthcare professionals coupled with advanced healthcare facilities within hospital settings has greatly contributed to revenue growth in the high-flow nasal cannula market.
Figure 1: High-Flow Nasal Cannula, by End-user, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
High-Flow Nasal Cannula Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The largest market share of the high-flow nasal cannula industry will come from the North American region mainly because it houses some top-performing markets globally. The reason behind its success lies in several factors. Firstly, there has been a rise in usage rates associated with these devices due to a higher number of recorded cases related to sleep apnea syndrome among people living on this side, which also happens to be one major cause of them being diagnosed with COPD. Secondly, the availability of advanced healthcare systems where even the most complex surgeries can be done successfully coupled up favorable reimbursement policies implemented by different governments over the years, making it easily affordable for patients to seek medical attention whenever required, thus leading to the dominance this particular industry across the United States among other countries around the world at large.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: HIGH-FLOW NASAL CANNULA SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe high-flow nasal cannula market accounts for the second-largest market share. Anticipated advancements in the region are expected to be propelled by a rise in respiratory diseases, increased recognition of the benefits of high-flow nasal cannula therapy, and a growing approval of noninvasive ventilation techniques. The industry is growing because of the large market leaders in the region. Further, the German high-flow nasal cannula market held the largest market share, and the UK high-flow nasal cannula market was the fastest growing market in the European region.
The Asia-Pacific High-Flow Nasal Cannula Market is expected to grow at the fastest CAGR from 2024 to 2032. The large and rapidly growing population with COPD and asthma, increasing the overall number of patients with respiratory illnesses and oxygen therapy needs, is one of many factors influencing the projected growth rate. Moreover, China’s high-flow nasal cannula market held the largest market share, and the Indian high-flow nasal cannula market was the fastest growing market in the Asia-Pacific region.
High-Flow Nasal Cannula Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the high-flow nasal cannula market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the high-flow nasal cannula industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global high-flow nasal cannula industry to benefit clients and increase the market sector. In recent years, the high-flow nasal cannula industry has offered some of the most significant advantages to medicine. Major players in the high-flow nasal cannula market are attempting to increase market demand by investing in research and development operations, including Fisher & Paykel Healthcare Limited, Teleflex Incorporated, ResMed, Devatec, Smiths Medical, Vapotherm, Hamilton Medical, Masimo (TNI medical AG), Flexicare Medical Limited, and Great Group Medical Co. Ltd.
With an emphasis on critical care, safety devices, and drug distribution, Smiths Medical produces medical equipment used in a range of therapeutic, diagnostic, and surgical procedures. The company's product line includes products for pain management, infusion devices, diabetes solutions, temperature management systems, drainage systems, respiratory systems, interventional imaging systems, safety solutions, anesthesia airway systems, tracheostomy products, vascular access devices, and ventilation systems.
Medical equipment is developed, manufactured, and distributed by ResMed Inc. (ResMed). The company provides its goods and services for the identification, therapy, and control of respiratory conditions, including chronic obstructive pulmonary disease (COPD), sleep apnea, and sleep-disordered breathing (SDB). Its main products are ventilation products, accessories, diagnostic products, masks, headgear, motors, and data/patient management products. Airflow generators include continuous positive airway pressure (CPAP), auto-bilevel, automatic positive airway pressure (APAP), variable positive airway pressure (VPAP), humidifiers, and ventilation products. ResMed Inc. announced the release of the AirSenseTM 11 device in 2021, which offers patients experiencing respiratory distress high-flow oxygen therapy. The new gadget is made to be both easy to use and adaptable to each patient's unique demands.
Key companies in the high-flow nasal cannula market include
High-Flow Nasal Cannula Industry Developments
January 2022: Smiths Medical was acquired by ICU Medical Inc. from Smiths Group plc with success. The acquisition includes a wide range of goods from Smiths Medical, including vital care items, vascular access solutions, and syringe and mobile infusion devices. With an expected pro forma combined revenue of roughly USD 2.5 billion, the combined firms create a prominent position as a leading infusion treatment company through the integration of Smiths Medical's business with ICU Medical's current activities.
February 2021: SoftFlow high-flow nasal cannula therapy was introduced by Masimo in the US. It supplies patients who are breathing on their own with high-flow nasal gases and high-flow heated and humidified respiratory gases. By producing a constant high flow of warm, humidified air or an air/oxygen mixture, the technology found on the softFlow 50 provides adult patients with high-flow respiratory support via a soft nasal cannula.
High-Flow Nasal Cannula Market Segmentation
High-Flow Nasal Cannula Component Outlook
- Nasal Cannulas
- Air Humidifiers
- Single Heated Tubes
- Air/Oxygen Blenders
- Others
High-Flow Nasal Cannula Application Outlook
- Carbon Monoxide Toxicity
- Acute Respiratory Failure
- Bronchiectasis
- Chronic Obstructive Pulmonary Disease (COPD)
- Sleep Apnea
- Others
High-Flow Nasal Cannula End-user Outlook
- Long-Term Care Centers
- Hospitals
- Ambulatory Care Services
- Others
High-Flow Nasal Cannula Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 7.9 Billion |
| Market Size 2024 |
USD 8.9 Billion |
| Market Size 2032 |
USD 21.0 Billion |
| Compound Annual Growth Rate (CAGR) |
13.00% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019-2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Component, Application, End-user, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Fisher & Paykel Healthcare Limited, Teleflex Incorporated, ResMed, Devatec, Smiths Medical, Vapotherm, Hamilton Medical, Masimo (TNI medical AG), Flexicare Medical Limited, and Great Group Medical Co. Ltd. |
| Key Market Opportunities |
·        Technological Developments in Nasal Cannula Systems with High Flow |
| Key Market Dynamics |
·        Growing Rate of Respiratory Conditions ·        Rising Healthcare Expenditure and Expanding Use of Ambulatory Surgery |
Frequently Asked Questions (FAQ) :
The High-Flow Nasal Cannula size was valued at USD 7.9 Billion in 2023.
The global market is projected to grow at a CAGR of 13.00% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Fisher & Paykel Healthcare Limited, Teleflex Incorporated, ResMed, Devatec, Smiths Medical, Vapotherm, Hamilton Medical, Masimo (TNI Medical AG), Flexicare Medical Limited, and Great Group Medical Co. Ltd.
The nasal cannulas category dominated the market in 2023.
The hospitals category had the largest share in the global market.
